Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Active-controlled Phase Ⅲ Clinical Trial to Evaluate the Immunogenicity and Safety of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated in Healthy People in Colombia

NCT05433272 is registered in ClinicalTrials.gov with Sinovac Biotech (Colombia) S.A.S. as lead sponsor.

NCT NCT05433272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05433272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Active-controlled Phase Ⅲ Clinical Trial to Evaluate the Immunogenicity and Safety of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated in Healthy People in Colombia
Lead sponsor
Sinovac Biotech (Colombia) S.A.S.
Phase
Phase 3
Overall status
Unknown status
Start date
August 10, 2023
Completion date
September 10, 2023
Enrollment
1,400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19